Ovid Therapeutics Inc.
OVID
$2.70
-$0.05-1.82%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 733.00K | -- | 718.00K | 132.00K | 6.27M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 733.00K | -- | 718.00K | 132.00K | 6.27M |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 733.00K | -- | 718.00K | 132.00K | 6.27M |
| SG&A Expenses | 6.17M | 6.67M | 6.42M | 6.79M | 4.88M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 16.13M | 17.85M | 13.01M | 12.66M | 11.35M |
| Operating Income | -15.40M | -17.85M | -12.29M | -12.52M | -5.07M |
| Income Before Tax | -15.01M | -16.99M | 9.66M | -12.16M | -4.68M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -15.01M | -16.99M | 9.66M | -12.16M | -4.68M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -15.01M | -16.99M | 9.66M | -12.16M | -4.68M |
| EBIT | -15.40M | -17.85M | -12.29M | -12.52M | -5.07M |
| EBITDA | -15.38M | -17.81M | -12.28M | -12.51M | -4.97M |
| EPS Basic | -0.08 | -0.12 | 0.12 | -0.17 | -0.06 |
| Normalized Basic EPS | -0.05 | -0.08 | -0.09 | -0.11 | -0.04 |
| EPS Diluted | -0.08 | -0.12 | 0.12 | -0.17 | -0.06 |
| Normalized Diluted EPS | -0.05 | -0.08 | -0.09 | -0.11 | -0.04 |
| Average Basic Shares Outstanding | 197.45M | 136.17M | 81.67M | 71.11M | 71.11M |
| Average Diluted Shares Outstanding | 197.45M | 136.17M | 81.67M | 71.11M | 71.11M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |